On the other hand, NR2F6 functions as an innate and adaptative immunity regulator: expressed in immune and stromal cells, promoting tumor escape from immune surveillance, resulting in poor outcomes for glioma patients. This evidence concerns the gene NR2F6 and central nervous system cancer.